Pharmaceuticals US

US Vaccine Adjuvants Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Vaccine Adjuvants Market Industry Trends and Forecast to 2034: Segmented by (Type, Application, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $315.5 Mn Placeholder estimate
Estimate 2025 $334.8 Mn 35.9% of the global market
Projected 2034 $570.4 Mn 70.4% Adds $235.7 Mn over 9 forecast years
CAGR 2025–2034 6.1% Faster than 51% of 180 Pharmaceuticals markets here
Key players 5
  • US is 35.88% of the global market.
  • In North America, the largest is US (this report) at $334.8 Mn.
  • Fastest growing: Canada at 8% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$235.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Vaccine Adjuvants Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $315.5 Mn — —
2025 (base) $334.8 Mn +$19.2 Mn —
2026 (forecast) $355.2 Mn +$20.4 Mn +6.1%
2027 (forecast) $376.9 Mn +$21.7 Mn +12.6%
2028 (forecast) $399.9 Mn +$23.0 Mn +19.4%
2029 (forecast) $424.3 Mn +$24.4 Mn +26.7%
2030 (forecast) $450.1 Mn +$25.9 Mn +34.5%
2031 (forecast) $477.6 Mn +$27.5 Mn +42.7%
2032 (forecast) $506.7 Mn +$29.1 Mn +51.4%
2033 (forecast) $537.6 Mn +$30.9 Mn +60.6%
2034 (forecast) $570.4 Mn +$32.8 Mn +70.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $933.1 Mn
  2. North America $504.4 Mn
  3. US (this report) $334.8 Mn
  4. Europe $189.0 Mn
  5. APAC $185.4 Mn
  6. Canada $82.0 Mn
  7. China $75.0 Mn
  8. Japan $63.3 Mn
  9. Latin America $37.7 Mn
  10. Middle East $32.6 Mn
  11. Germany $30.7 Mn
  12. France $27.9 Mn
  13. UK $26.5 Mn
  14. Brazil $25.8 Mn
  15. Italy $23.2 Mn
  16. Ecuador $18.7 Mn
  17. India $17.7 Mn
  18. Spain $15.9 Mn
  19. Africa $16.2 Mn
  20. Mexico $15.4 Mn
  21. Saudi Arabia $14.3 Mn
  22. Australia $12.6 Mn
  23. New Zealand $9.5 Mn
  24. Russia $9.0 Mn
  25. South Africa $5.8 Mn
  26. UAE $5.2 Mn
  27. Egypt $2.6 Mn
  28. Philippines $2.2 Mn
  29. Hong Kong $1.5 Mn
  30. Malaysia $1.3 Mn
  31. Singapore $1.1 Mn
  32. Thailand $0.9 Mn
  33. Kenya $0.6 Mn

Report snapshot

US Vaccine Adjuvants Market Analysis at a glance
Market size, 2025$334.8 Mn placeholder estimate
Forecast, 2034$570.4 Mn placeholder estimate
Growth (CAGR), 2025–20346.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType and application (see all)
Key playersGSK PLC, Novavax, Croda International PLC, SEPPIC (Air Liquide), Dynavax Technologies (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Vaccine Adjuvants Market Analysis Executive Summary

Vaccine adjuvants are ingredients added to vaccines to make the immune response stronger and longer-lasting.

Key segments of the vaccine Adjuvants market include type (Aluminum Salts, Emulsions and Saponin-Based) and application (Human Vaccines and Veterinary Vaccines).

Bar chart: US Vaccine Adjuvants market size, 2024–2034, placeholder estimates. $315.5 Mn in 2024, $334.8 Mn in 2025 and $570.4 Mn in 2034, 6.1% CAGR.
US Vaccine Adjuvants market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Vaccine Adjuvants Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the vaccine Adjuvants market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the vaccine Adjuvants market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the vaccine Adjuvants market.

Competitive Landscape for Vaccine Adjuvants Market in US

The vaccine Adjuvants market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Vaccine Adjuvants Market in US

Vaccine Adjuvants in the US: rules and payment

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for vaccine Adjuvants. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Vaccine Adjuvants right now, from free public sources.

Latest research 807 papers since 2021 (worldwide)

  1. Rationally Designed TLR2-QS-21 Liposomal Adjuvant Enhances Immunogenicity while Reducing Reactogenicity in Subunit Vaccines. Journal of medicinal chemistry, 2026
  2. Poly-γ-Glutamic Acid-Modified Carbon Dots as an Enhanced Immune-Activating and Antigen-Delivering Nano-adjuvant for Improved Influenza Vaccine Efficacy. ACS applied materials & interfaces, 2026
  3. Editing the C2 Position of Glycolipid Ligands Reveals Ligand-Dependent Recognition by Mincle. ACS chemical biology, 2026
  4. Immunological Basis of Vaccine Adjuvants: From Licensed Platforms to Next-Generation Design. Immune network, 2026
  5. Disruption of the polyuracil tract can greatly enhance immunostimulatory properties of influenza delVGs. bioRxiv : the preprint server for biology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Vaccine Adjuvants in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Vaccine Adjuvants market in the US?
Placeholder estimate: about $334.8 Mn in 2025, rising to about $570.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Vaccine Adjuvants market in the US growing?
Placeholder estimate: about 6.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Vaccine Adjuvants market report cover?
The report splits the market by type (Aluminum Salts, Emulsions, Saponin-Based, TLR Agonists) and application (Human Vaccines, Veterinary Vaccines).
Who are the key players in the Vaccine Adjuvants market?
Key players include GSK PLC, Novavax, Croda International PLC, SEPPIC (Air Liquide) and Dynavax Technologies.
What is driving the Vaccine Adjuvants market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the vaccine Adjuvants market.
Who regulates Vaccine Adjuvants in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How much research is published on Vaccine Adjuvants?
PubMed lists 807 papers on Vaccine Adjuvants added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Vaccine Adjuvants in US? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in US

See all
Same topic, other categories

Related on vaccines and biologics and biosimilars

See the topic